Drug Type Monoclonal antibody |
Synonyms ADA-011 |
Target |
Mechanism LILRB inhibitors(Leukocyte immunoglobulin-like receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Adanate, Inc.Startup |
Active Organization Adanate, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | Adanate, Inc.Startup | 15 Nov 2022 |
Solid tumor | Phase 1 | US | Adanate, Inc.Startup | 10 Dec 2021 |